Frequency Therapeutics Inc

+0.37 (+3.67%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)357.59M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.71 Million
Adjusted EPS-$0.51
See more estimates
10-Day MA$9.92
50-Day MA$9.66
200-Day MA$24.89
See more pivots

Frequency Therapeutics Inc Stock, NASDAQ:FREQ

75 Hayden Avenue, Suite 300, Lexington, Massachusetts 02421
United States of America
Phone: +1.781.315.466
Number of Employees: 87


Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The firm's progenitor cell activation approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.